TY - JOUR
T1 - Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation
T2 - The NOVEL study
AU - Tsuburaya, Ryuji
AU - Takahashi, Jun
AU - Nakamura, Akihiro
AU - Nozaki, Eiji
AU - Sugi, Masafumi
AU - Yamamoto, Yoshito
AU - Hiramoto, Tetsuya
AU - Horiguchi, Satoru
AU - Inoue, Kanichi
AU - Goto, Toshikazu
AU - Kato, Atsushi
AU - Shinozaki, Tsuyoshi
AU - Ishida, Eiko
AU - Miyata, Satoshi
AU - Yasuda, Satoshi
AU - Shimokawa, Hiroaki
N1 - Publisher Copyright:
© 2016 Published on behalf of the European Society of Cardiology. All rights reserved.
PY - 2016/9/14
Y1 - 2016/9/14
N2 - Aims It is widely known that drug-eluting stents (DES) induce coronary vasomotion abnormalities. We have previously demonstrated that chronic treatment with long-acting nifedipine suppresses coronary hyperconstricting responses induced by the first-generation DES (e.g. sirolimus- and pacritaxel-eluting stents) through inhibition of vascular inflammation in pigs. To examine whether this is also the case with the second-generation DES (everolimus-eluting stents, EES) in humans, the most widely used DES in the world, we conducted a prospective, randomized, multicentre trial, termed as the NOVEL Study. Methods and results We evaluated 100 patients with stable angina pectoris who underwent scheduled implantation of EES in the left coronary arteries. They were randomly assigned to receive either conventional treatments alone or additionally long-acting nifedipine (10-60 mg/day) (n = 50 each). After 8-10 months, 37 patients in the control and 38 in the nifedipine group were examined for coronary vasoreactivity to intracoronary acetylcholine (ACh) by quantitative coronary angiography after 48-h withdrawal of nifedipine. Coronary vasoconstricting responses to ACh were significantly enhanced at the distal edge of EES compared with non-stented vessel (P = 0.0001) and were significantly suppressed in the nifedipine group compared with the control group (P = 0.0044). Furthermore, the inflammatory profiles were also improved only in the nifedipine group, which evaluated by serum levels of high-sensitivity CRP (P = 0.0001) and adiponectin (P = 0.0039). Conclusions These results indicate that DES-induced coronary vasomotion abnormalities still remain an important clinical issue even with the second-generation DES, for which long-acting nifedipine exerts beneficial effects associated with its anti-inflammatory effects. Trial Registration: This study is registered at the UMIN Clinical Trial Registry (UMIN-CTR; ID=UMIN000015147).
AB - Aims It is widely known that drug-eluting stents (DES) induce coronary vasomotion abnormalities. We have previously demonstrated that chronic treatment with long-acting nifedipine suppresses coronary hyperconstricting responses induced by the first-generation DES (e.g. sirolimus- and pacritaxel-eluting stents) through inhibition of vascular inflammation in pigs. To examine whether this is also the case with the second-generation DES (everolimus-eluting stents, EES) in humans, the most widely used DES in the world, we conducted a prospective, randomized, multicentre trial, termed as the NOVEL Study. Methods and results We evaluated 100 patients with stable angina pectoris who underwent scheduled implantation of EES in the left coronary arteries. They were randomly assigned to receive either conventional treatments alone or additionally long-acting nifedipine (10-60 mg/day) (n = 50 each). After 8-10 months, 37 patients in the control and 38 in the nifedipine group were examined for coronary vasoreactivity to intracoronary acetylcholine (ACh) by quantitative coronary angiography after 48-h withdrawal of nifedipine. Coronary vasoconstricting responses to ACh were significantly enhanced at the distal edge of EES compared with non-stented vessel (P = 0.0001) and were significantly suppressed in the nifedipine group compared with the control group (P = 0.0044). Furthermore, the inflammatory profiles were also improved only in the nifedipine group, which evaluated by serum levels of high-sensitivity CRP (P = 0.0001) and adiponectin (P = 0.0039). Conclusions These results indicate that DES-induced coronary vasomotion abnormalities still remain an important clinical issue even with the second-generation DES, for which long-acting nifedipine exerts beneficial effects associated with its anti-inflammatory effects. Trial Registration: This study is registered at the UMIN Clinical Trial Registry (UMIN-CTR; ID=UMIN000015147).
KW - Calcium channel blockers
KW - Coronary spasm
KW - Drug-eluting stents
UR - http://www.scopus.com/inward/record.url?scp=84990954632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990954632&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehw256
DO - 10.1093/eurheartj/ehw256
M3 - Article
C2 - 27354043
AN - SCOPUS:84990954632
SN - 0195-668X
VL - 37
SP - 2713
EP - 2721
JO - European Heart Journal
JF - European Heart Journal
IS - 35
ER -